Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANTABRICO: Durvalumab plus platinum-etoposide in first-line extensive-stage small cell lung cancer
2020-002328-35Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Primary endpoint: Incidence of grade ≥ 3 adverse events. Started Feb 2021; status: active.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2020-002328-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002328-35.